X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FRESENIUS KABI ONCO. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FRESENIUS KABI ONCO. ABBOTT INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 39.4 22.1 177.8% View Chart
P/BV x 11.4 3.1 365.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ABBOTT INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs5,190176 2,948.9%   
Low Rs4,35179 5,542.7%   
Sales per share (Unadj.) Rs1,382.937.7 3,669.6%  
Earnings per share (Unadj.) Rs130.25.1 2,556.1%  
Cash flow per share (Unadj.) Rs137.96.7 2,051.4%  
Dividends per share (Unadj.) Rs40.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs652.742.5 1,534.1%  
Shares outstanding (eoy) m21.25158.23 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 102.2%   
Avg P/E ratio x36.625.0 146.7%  
P/CF ratio (eoy) x34.618.9 182.7%  
Price / Book Value ratio x7.33.0 244.4%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m101,37320,135 503.5%   
No. of employees `0003.11.2 267.6%   
Total wages/salary Rs m3,453703 491.0%   
Avg. sales/employee Rs Th9,531.95,176.2 184.1%   
Avg. wages/employee Rs Th1,119.9610.4 183.5%   
Avg. net profit/employee Rs Th897.3699.6 128.3%   
INCOME DATA
Net Sales Rs m29,3875,963 492.8%  
Other income Rs m57618 3,202.2%   
Total revenues Rs m29,9635,981 501.0%   
Gross profit Rs m3,9731,430 277.8%  
Depreciation Rs m164258 63.7%   
Interest Rs m20-26 -78.5%   
Profit before tax Rs m4,3651,216 358.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,598342 467.1%   
Profit after tax Rs m2,767806 343.3%  
Gross profit margin %13.524.0 56.4%  
Effective tax rate %36.628.1 130.1%   
Net profit margin %9.413.5 69.7%  
BALANCE SHEET DATA
Current assets Rs m18,9065,102 370.6%   
Current liabilities Rs m6,2972,385 264.0%   
Net working cap to sales %42.945.6 94.2%  
Current ratio x3.02.1 140.4%  
Inventory Days Days62150 41.4%  
Debtors Days Days22113 19.1%  
Net fixed assets Rs m1,1595,148 22.5%   
Share capital Rs m213158 134.3%   
"Free" reserves Rs m13,6576,556 208.3%   
Net worth Rs m13,8696,732 206.0%   
Long term debt Rs m0952 0.0%   
Total assets Rs m20,63810,388 198.7%  
Interest coverage x215.0-45.8 -469.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.40.6 248.1%   
Return on assets %13.57.5 179.9%  
Return on equity %19.912.0 166.6%  
Return on capital %31.614.6 216.5%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m05,298 0.0%   
Fx outflow Rs m01,772 0.0%   
Net fx Rs m03,525 0.0%   
CASH FLOW
From Operations Rs m3,0721,274 241.1%  
From Investments Rs m-1,554-1,204 129.1%  
From Financial Activity Rs m-898-196 457.7%  
Net Cashflow Rs m621-126 -491.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 9.6 1.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 42,599 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - FDC LTD. COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS